Center-Authored Papers

Filters: Author is Fero, Matthew  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Beier R, Bürgin A, Kiermaier A, Fero M, Karsunky H, Saffrich R, Möröy T, Ansorge W, Roberts J, Eilers M.  2000.  Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events.. The EMBO journal. 19(21):5813-23. Abstract
C
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ.  1999.  The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.. The EMBO journal. 18(6):1571-83. Abstract
Chien W-M, Rabin S, Macias E, Miliani de Marval PL, Garrison K, Orthel J, Rodriguez-Puebla M, Fero ML.  2006.  Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1.. Proceedings of the National Academy of Sciences of the United States of America. 103(11):4122-7. Abstract
Chien WM, Garrison K, Orthel J, Rabin S, Fero ML.  2005.  Tissue specific knockout and knockon mutations of p27Kip1. Cold Spring Harbor 70th Symposium .
Chien W-M, Garrison K, Caufield E, Orthel J, Dill J, Fero ML.  2007.  Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis.. Cell cycle (Georgetown, Tex.). 6(6):750-7. Abstract
Chien WM, Caufield E, Orthel J, Rabin S, Fero ML.  2004.  Cre-Lox mediated Knockout and Knockon mouse models and radiation chimeras reveal both cell autonomous and cell non-autonomous mechanisms of growth and tumor suppression by p27Kip1. American Association of Cancer Researchers Annual Meeting .
Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randel E, Firpo E, Roberts JM.  1999.  A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.. Current biology : CB. 9(4):163-73. Abstract
D
Durand B, Fero ML, Roberts JM, Raff MC.  1998.  p27Kip1 alters the response of cells to mitogen and is part of a cell-intrinsic timer that arrests the cell cycle and initiates differentiation.. Current biology : CB. 8(8):431-40. Abstract
F
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM et al..  1996.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.. Cell. 85(5):733-44. Abstract
Fero ML.  2008.  Doping: ignorance of basic statistics is all too common.. Nature. 455(7210):166.
Fero ML, Randel E, Gurley K, Roberts J, Kemp C.  1998.  p27kip1: A Haploinsufficient Tumor Suppressor. Gordon Conference on DNA alterations in transformed cells .
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Perlmutter R, Kaushanski K, Brody E, Roberts J.  1996.  Increased Growth and Tumor Development in P27kip1-Knockout Mice .
Fero ML, Kuppers D, Hwang H, Clurman B, Jackson A, Linsley P.  2008.  Altered T-cell differentiation, gene expression and lymphomagenesis by miR-106-363. Keystone Symposia: RNAi, MicroRNA, and Non-Coding RNA.
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ.  1998.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression.. Nature. 396(6707):177-80. Abstract
Fero ML, Kemp CJ.  2002.  p27 (Kip1) . The Encylopedia of Molecular Medicine. :2363-2366.
Fero ML, Lowenheim H, Gu R, Sudra A, Kil J.  1999.  Regeneration of Auditory Sensory Cells Via p27Kip1 Antagonism. Cold Spring Harbor Cell Cycle Symposium .
Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem H-P, Petersdorf EW, Pereira S, Nash RA, Mielcarek M, Fero ML et al..  2011.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.. Blood. 117(11):3214-9. Abstract
Flowers MED, Storer BE, Carpenter PA, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem H-P, Fero ML, Georges GE et al..  2008.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(12):1380-4. Abstract
G
Garrett-Engele CM, Tasch MA, Hwang HC, Fero ML, Perlmutter RM, Clurman BE, Roberts JM.  2007.  A mechanism misregulating p27 in tumors discovered in a functional genomic screen.. PLoS genetics. 3(12):e219. Abstract
Glover CE, Gurley KE, Kim K-H, Storer BE, Fero ML, Kemp CJ.  2009.  Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer.. Carcinogenesis. 30(6):1058-63. Abstract
Godin JD, Thomas N, Laguesse S, Malinouskaya L, Close P, Malaise O, Purnelle A, Raineteau O, Campbell K, Fero M et al..  2012.  p27(Kip1) Is a Microtubule-Associated Protein that Promotes Microtubule Polymerization during Neuron Migration.. Developmental cell. 23(4):729-44. Abstract
Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M.  2015.  Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.. Cancer. Abstract
H
Hatton BA, Ellison DW, Gajjar A, Kool M, Fero M, Olson JM.  2013.  Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.. Biomarker research. 1(1):14. Abstract
Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ.  1999.  Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1).. The Journal of clinical investigation. 103(5):597-604. Abstract
Hwang H, Chien WM, Jackson A, Guo K, Clurman B, Fero ML.  2006.  The CDK inhibitor p27Kip1 collaborates with miRNA overexpression to induce murine lymphomas. Cold Spring Harbor Mechanisms & Models of Cancer Meeting .